vimarsana.com

Latest Breaking News On - Parkman healthcare partners - Page 7 : vimarsana.com

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 1,050,000 shares, a decrease of 15.3% from the March 31st total of 1,240,000 shares. Based on an average daily volume of 341,300 shares, […]

Chicago
Illinois
United-states
Acumen-pharmaceuticals
Jump-financial
Acumen-pharmaceuticals-company-profile
Acumen-pharmaceuticals-trading
News-ratings-for-acumen-pharmaceuticals-daily
Acumen-pharmaceuticals-inc
Franklin-resources-inc
Parkman-healthcare-partners

Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright

Syndax Pharmaceuticals' (SNDX) "Buy" Rating Reaffirmed at HC Wainwright
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Scotiabank
Syndax-pharmaceuticals-inc
Syndax-pharmaceuticals-stock-performance
Nasdaq
Analyst-recommendations-for-syndax-pharmaceuticals
News-ratings-for-syndax-pharmaceuticals-daily
Parkman-healthcare-partners
Syndax-pharmaceuticals
Vanguard-group-inc
Jpmorgan-chase-co
Institutional-investors-weigh-in-on-syndax-pharmaceuticals

Morgan Stanley Reiterates "Overweight" Rating for Silence Therapeutics (NASDAQ:SLN)

Morgan Stanley Reiterates "Overweight" Rating for Silence Therapeutics (NASDAQ:SLN)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Parkman-healthcare-partners
Vivo-capital
Morgan-stanley
Sg-americas-securities
Silence-therapeutics
Free-report
Therapeutics-trading-down
Get-free-report
Healthcare-partners
Oligonucleotide-discovery
Silence-therapeutics-daily

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Forecasted to Post Q2 2024 Earnings of ($0.06) Per Share

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Forecasted to Post Q2 2024 Earnings of ($0.06) Per Share
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Sanjk-patel
Michaelr-megna
Nasdaq
News-ratings-for-kiniksa-pharmaceuticals-daily
Kiniksa-pharmaceuticals-company-profile
Kiniksa-pharmaceuticals-ltd
Granahan-investment-management
Institutional-trading-of-kiniksa-pharmaceuticals
Parkman-healthcare-partners
Opaleye-management-inc
Allspring-global-investments-holdings
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.